Bladder cancer is the fourth most common cancer among adult men. In recent decades, however, research and treatment innovation for this disease have lagged. Thomas Flaig, MD, vice chancellor of research for CU Denver and the CU Anschutz Medical Campus, recently presented findings from a 10-year-long effort to study bladder cancer biomarker development and treatment.
We spoke with Flaig, a CU Cancer Center member, on the recent abstract that he presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco.